Investment analysts at Jefferies Group boosted their price target on shares of Mallinckrodt PLC (NYSE:MNK) from $77.00 to $85.00 in a note issued to investors on Monday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective suggests a potential upside of 16.15% from the stock’s previous close. Mallinckrodt PLC (NYSE:MNK) net profit margin is 3.80% and weekly performance is 7.88%. On last trading day company shares ended up $78.86. Analysts mean target price for the company is $81.80. Mallinckrodt PLC (NYSE:MNK) distance from 50-day simple moving average (SMA50) is 17.15%.
Several generic companies including Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)/Sandoz Inc., a subsidiary of Novartis ( NVS ) and Mylan /Natco Pharmaceuticals are looking to get their generic versions of Copaxone in the market. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares advanced 0.17% in last trading session and ended the day on $11.95. MNTA return on assets is -30.90%. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) quarterly performance is -33.05%.
In November, AstraZeneca sold U.S. rights to Vimovo to Horizon Pharma Inc (NASDAQ:HZNP), but that deal still gives Pozen a 10% royalty on net U.S. sales, with guaranteed annual minimum royalty payments of $5 million in 2014, and $7.5 million each year thereafter—as long as the patents are still in effect and no generic versions are on the market. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -0.62% in last trading session and was closed at $12.88, while trading in range of $12.55 – $13.10. Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 69.03%.
Evoke Pharma Inc (NASDAQ:EVOK) announced its earnings results on Tuesday. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.36) by $0.13, StockRatingsNetwork reports. Evoke Pharma Inc (NASDAQ:EVOK) ended the last trading day at $6.77. Company weekly volatility is calculated as 5.18% and price to cash ratio as 1.74. Evoke Pharma Inc (NASDAQ:EVOK) showed a negative weekly performance of -15.49%.
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) is as a Florida-based development-stage specialty pharmaceutical company. Catalyst’s major product is Firdapse which is used to treat Lambert-Eaton Myasthenic Syndrome (“LEMS”). Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) weekly performance is 5.20%. On last trading day company shares ended up $1.82. Analysts mean target price for the company is $4.55. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) distance from 50-day simple moving average (SMA50) is -13.20%.